Latest in Finance

Pfizer clinches $10bn deal to acquire weight-loss biotech Metsera after bidding war with Novo Nordisk

Metsera says that it has opted for Pfizer's revised deal after antitrust concerns surrounding rival Novo's bid for the biotech

Find out more

You need to be a subscriber to read this article.
Click here to find out more.

Three ways AI is changing the chemicals and materials industry

With AI technologies continuing to make their mark on almost every sector, the materials and chemicals industry is no exception, reports Cameron Ross, Senior Vice President of...
See more

Pfizer denied restraining order on rival Novo Nordisk in GLP-1 bidding war

The Delaware Chancery Judge rejected Pfizer's request for a temporary restraining order, arguing that the company's objections to Novo's proposed deal weren't a legitimate reason for stopping the competitor's offer

Custom Pharmaceuticals launches new company to foster breakthrough drug development and strategic partnerships

Custom Pharmaceuticals Ltd has launched Centrix Pharma Solutions, a new company dedicated to accelerating drug product development through collaboration with biotech firms and academic research

Metsera declares $10bn Novo deal "superior" after Pfizer files second lawsuit in GLP-1 row

Metsera has said Novo Nordisk’s revised offer is a “superior proposal” to Pfizer’s, escalating a high-stakes legal and acquisition battle and where Pfizer has filed a second lawsuit accusing Novo of anticompetitive behaviour and Metsera of collusion

Kimberley-Clark to acquire Tylenol maker Kenvue in landmark $40bn deal

The transaction brings together two iconic American companies to create a combined portfolio of complementary products, including 10 billion-dollar brands, that touch nearly half the global population through every stage of life

Pfizer sues Metsera and Novo Nordisk over alleged breach of merger agreement

Pfizer has filed a lawsuit against Metsera, its Board of Directors and Novo Nordisk, alleging breach of contract, fiduciary duty and interference following Metsera’s decision to pursue a rival offer that Pfizer claims is “illegal”

Lonza to expand bioscience testing offering with the acquisition of Redberry

Acquisition to include Red One solid-phase cytometry platform for rapid sterility and bioburden testing, which expands Lonza’s portfolio of automated, scalable solutions for pharmaceutical quality control (QC)

Shilpa Medicare opens flow chemistry manufacturing centre

The flow chemistry centre of excellence includes more than 100 R&D and manufacturing scientists

Aseptic spray drying: Transforming biotherapeutics for a new era

With interest in aseptic spray drying on the rise in the pharmaceutical industry, Dr Kevin Robinson spoke to GEA’s David Costes about how the company is combining process, engineering and technological expertise with market insights to provide a safe, reliable and high-performance technology for advanced biotherapeutic powder applications

Latest posts in Finance

Cambrex unveils $120m investment to expand API manufacturing and strengthen US drug supply resilience

Cambrex's continued investments underscore its commitment to adding capabilities and increasing capacity to meet the evolving needs and growing demand of the pharmaceutical industry.

Curia invests $4m to enhance sterile API manufacturing

The investment aligns with the latest EU GMP Annex 1 standards and reinforces Curia’s longstanding commitment to regulatory excellence and product quality

Agarose Bead Technologies marks 25 years with $10m global expansion plan

The Spanish agarose resin specialist will expand into the US and India, invest in scalable bioprocessing technologies and enhance sustainability across its European facilities to meet growing demand for advanced therapy purification

Sharp Services invests $100m to expand global sterile and packaging capacity across US and Europe

The investment will boost sterile fill/finish, injectable packaging and oral solid dose capacity across Sharp's US and European sites, strengthening its clinical and commercial manufacturing network to meet growing pharmaceutical demand

MilliporeSigma to acquire JSR Life Sciences’ chromatography business, boosting Protein A purification capabilities

The acquisition expands MilliporeSigma’s downstream bioprocessing portfolio with JSR’s Amsphere Protein A resin technology, enhancing efficiency and reliability in monoclonal antibody and therapeutic protein production

Wilmington PharmaTech secures further funding for its expansion from Curewell Capital

The CDMO's partnership with Curewell will provide significant growth capital to expand WPT’s manufacturing capacity and further scale its end-to-end capabilities in producing a full range of small molecule API in the US

MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results

The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled

Novo Nordisk acquires rights to Omeros’ MASP-3 inhibitor zaltenibart in $2.1bn deal

The agreement grants Novo Nordisk exclusive global rights to develop and commercialise the clinical-stage antibody for rare blood and kidney disorders, strengthening its Rare Disease portfolio

Kailera Therapeutics secures $600m in Series B financing to advance next-generation obesity therapies

The funding will support the advancement of Kailera’s obesity portfolio, including a global Phase III clinical programme of Kailera’s lead candidate KAI-9531, an injectable dual GLP-1/GIP receptor agonist with potentially best-in-category weight loss

LTS expands CDMO footprint with acquisition of Renaissance Lakewood

LTS Lohmann Therapie-Systeme has agreed to acquire US-based CDMO Renaissance Lakewood, strengthening its position in nasal spray and sterile dosage form manufacturing and broadening its global drug delivery capabilities

Nanoform collaborates with A.forall and IMGA to outlicence Nanoencorafenib

Nanoform will establish a new company, BRAFMed, to progress the clinical development and future outlicensing of the patient-centric nanoformulation of encorafenib

Sponsor content

Piramal Pharma reports Q2 and H1 FY26 results amid CDMO challenges

CDMO growth impacted by inventory destocking while consumer healthcare posts mid-teen growth

Gerresheimer adjusts 2025 guidance amid slower market growth

Transformation program launched to boost performance and free cash flow

GEA raises guidance following strong H1 performance

Revised forecast reflects improved margins, robust order intake and efficiency gains

Lonza delivers strong H1 2025 performance

Lonza delivers strong H1 2025 performance and upgrades 2025 full-year CDMO sales and margin outlook

Gerresheimer reports H1 2025 growth driven by Bormioli Pharma acquisition

Cosmetics and oral liquids markets dampen organic revenue but outlook remains strong

Almac completes a multi-million-pound investment enhancing cold chain capabilities in Craigavon

Almac Clinical Services, part of the Almac Group, has completed a multi-million-pound investment to enhance cold chain capabilities at its global headquarters in...

CARBOGEN AMCIS accelerates manufacturing capacity with CHF 25.5 million co-investment at Swiss sites

CARBOGEN AMCIS is pleased to announce a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at...

Gerresheimer adjusts guidance for Financial Year 2025

Gerresheimer is adjusting its guidance for 2025 due to continuing subdued demand in the cosmetics market and a decline in demand for plastic containment solutions for oral...

Almac Group hits record £1 billion revenue milestone

Strong financials support expansion in manufacturing and clinical capabilities

Lonza publishes updated 2024 financials ahead of One Lonza reporting

New CDMO platform structure supports upcoming half-year 2025 results

Vetter once again named best managed company

The award jury recognises strategic and sustainable corporate management

SCHOTT Pharma delivers strong second quarter of fiscal year 2025

SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, today published its results for the second quarter of the fiscal year 2025